Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
RAPID MICRO BIOSYSTEMS, INC. (RPID) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores RPID at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,619 of 2,962 stocks — the bottom half of the AI-ranked universe. RPID scores in the top quartile across institutional flow (92.1), revenue growth (82.6). Areas of concern include balance sheet strength (1.8) and free cash flow (6.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RAPID MICRO BIOSYSTEMS, INC. reports quarterly revenue of $8.1M, net income of $-12.9M, free cash flow of $-12.9M. Top institutional holders of RPID by reported 13-F value include Bain Capital Life Sciences Investors, ARMISTICE CAPITAL, ABG-WTT Global Life Science Capital Partners GP Ltd, based on the most recent SEC filings. RPID trades on the Nasdaq exchange and files with the SEC under CIK 1380106. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RPID daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RAPID MICRO BIOSYSTEMS, INC. directly from SEC EDGAR.
AI Quality Score
26.5/100
AI Rank
#2,619
Revenue
$8.1M
Net Income
$-12.9M
Free Cash Flow
$-12.9M
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $33.6M | $-47.1M | -141.1% |
| FY 2024 | 10-K | $28.1M | $-46.9M | -178.0% |
| FY 2023 | 10-K | $22.5M | $-52.5M | — |
| FY 2022 | 10-K | $17.1M | $-60.8M | — |
| FY 2021 | 10-K | $23.2M | $-73.5M | — |
| FY 2020 | 10-K | $16.1M | $-37.1M | -190.0% |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| Bain Capital Life Sciences Investors | 8,434,560 | $14.6M | 2026-06-30 |
| ARMISTICE CAPITAL | 3,328,000 | $5.8M | 2026-06-30 |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 1,848,296 | $3.2M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT | 982,034 | $1.7M | 2026-06-30 |
| Evernest Financial Advisors | 506,000 | $875.4K | 2026-06-30 |
| ADVENT INTERNATIONAL, L.P. | 379,794 | $657.0K | 2026-06-30 |
| ESSEX INVESTMENT MANAGEMENT | 362,696 | $627.5K | 2026-06-30 |
| MILLENNIUM MANAGEMENT | 236,599 | $409.3K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT | 228,041 | $394.7K | 2026-06-30 |
| RENAISSANCE TECHNOLOGIES | 212,101 | $366.9K | 2026-06-30 |
13F Pro Quality Score
Rank #2,619 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk